Multimodal Assesment of Alzheimer Patients
Multimodal Assessment of Cognitive Impairment in Alzheimer Patients
Norwegian University of Science and Technology
60 participants
Jul 1, 2024
OBSERVATIONAL
Conditions
Summary
The goal of this study is to learn more about the changes in the brains of patients with cognitive impairment (MCI) and Alzheimer's Disease (AD). The main questions the study aims to answer are: 1. What findings can be used to earlier detect patients that will develop Alzheimers? 2. Which differences are seen between healthy and cognitively impaired patients? 3. Which differences are seen between patients with Alzheimers disease? Participants will undergo: * Cognitive tests * Magnetic resonance imaging (MRI) * Electroencephalography (EEG) * Blood sample collection * Fecal sample collection * A randomized group will undergo polysomnography analysis.
Eligibility
Inclusion Criteria2
- MCI and AD according to relevant ICD-criterias.
- Control cohort is age and gender matched with other cohorts.
Exclusion Criteria7
- Uneligibility for any of the planned neuroimagery devices (MRI, EEG)
- AD diagnosis before the age of 65 (Early-onset AD).
- Brain tumor
- Traumtic head injury
- Earlier neurosurgery
- Other neyrodegenerative diseases (i.e Parkinson and ALS)
- Diseases related to inflammation and auto-immunity (i.e MS)
Interventions
MRI scanning with volumetric, resting and activity-based sequences.
EEG to quantifiy electric activity.
A randomized group will undergo polysomnography.
Analysis of specific blood biomarkers.
Analysis of bacterial composition.
Interview-based cognitive tests for assesment of cognitive levels.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06448403